We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

96 hedge funds and large institutions have $172M invested in Rigel Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 41 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $153M → $172M (+$19.7M)

8% less funds holding

Funds holding: 104 → 96 (-8)

33% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 18

44% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 41

Holders
96
Holders Change
-8
Holders Change %
-7.69%
% of All Funds
2.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
23
Reduced
41
Closed
18
Calls
$3K
Puts
–
Net Calls
+$3K
Net Calls Change
+$2K

Top Buyers

1
BC
Broadfin Capital
New York
+$5.06M
2
DCM
DAFNA Capital Management
California
+$1.51M
3
California Public Employees Retirement System
California Public Employees Retirement System
California
+$1.16M
4
Marshall Wace
Marshall Wace
United Kingdom
+$735K
5
OAM
Oxford Asset Management
United Kingdom
+$376K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$2.2M
2
BFA
BlackRock Fund Advisors
California
-$1.55M
3
TC
TFS Capital
Pennsylvania
-$1.54M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$1.48M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$1.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$29.9M – – –
BC
2
Broadfin Capital
New York
$19.3M +$5.06M +250,373 +42%
PAI
3
Palo Alto Investors
California
$11.8M -$7.64K -378 -0.1%
O
4
OppenheimerFunds
New York
$11.3M – – –
Wellington Management Group
5
Wellington Management Group
Massachusetts
$11.2M -$45.5K -2,248 -0.5%
BIT
6
BlackRock Institutional Trust
California
$7.41M -$111K -5,480 -2%
NMC
7
NEA Management Company
Maryland
$7.36M – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$6.8M -$1.48M -73,124 -20%
BFA
9
BlackRock Fund Advisors
California
$5.46M -$1.55M -76,629 -24%
DM
10
Deerfield Management
New York
$5.44M – – –
SAM
11
Senzar Asset Management
New York
$4.81M +$88.2K +4,359 +2%
Millennium Management
12
Millennium Management
New York
$4.47M -$2.2M -108,694 -36%
UBS AM
13
UBS AM
Illinois
$4.44M -$64.9K -3,210 -2%
D.E. Shaw & Co
14
D.E. Shaw & Co
New York
$3.54M +$93K +4,598 +3%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$3.3M -$163K -8,048 -5%
State Street
16
State Street
Massachusetts
$3.27M -$118K -5,845 -4%
Northern Trust
17
Northern Trust
Illinois
$2.04M -$125K -6,182 -6%
DCM
18
DAFNA Capital Management
California
$1.7M +$1.51M +74,907 New
VAM
19
Visium Asset Management
New York
$1.37M – – –
California Public Employees Retirement System
20
California Public Employees Retirement System
California
$1.36M +$1.16M +57,450 +1,004%
BA
21
BlackRock Advisors
Delaware
$1.24M -$972K -48,073 -47%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$1.22M +$27.7K +1,372 +3%
Renaissance Technologies
23
Renaissance Technologies
New York
$1.17M -$147K -7,260 -12%
BBA
24
Baker Bros. Advisors
New York
$1.09M – – –
Jacobs Levy Equity Management
25
Jacobs Levy Equity Management
New Jersey
$1.09M -$38.3K -1,893 -4%
1
2 3 4 5

RIGL Hedge Fund Activity: Q4 2014 in Review

96 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q4 2014, worth a combined $172M — up 13% from $153M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of RIGL and 12 opened new positions — a net loss of 6 holders — while 41 trimmed existing stakes and 23 added.

The largest buyer was Broadfin Capital, adding an estimated $5.06M. The largest seller was Millennium Management, cutting an estimated $2.2M.

  • 96 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q4 2014, down from 104 in Q3 2014.
  • Funds reported $172M of Rigel Pharmaceuticals stock for Q4 2014, up 13% quarter-over-quarter.
  • 12 funds opened new Rigel Pharmaceuticals positions in Q4 2014 and 18 closed out, a net change of -6 holders.
  • The largest Rigel Pharmaceuticals buyer in Q4 2014 was Broadfin Capital, an estimated $5.06M added.
  • The largest Rigel Pharmaceuticals seller in Q4 2014 was Millennium Management, an estimated $2.2M sold.

Based on aggregated 13F filings for Q4 2014.